Ganitumab

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameGanitumab
Drug Alias NameAMG-479
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInsulin-like growth factor I receptor antagonists
TargetsInsulin-like growth factor I receptor
Therapy Area/IndicationsBone metastasesSolid tumoursNeoplasm Metastasis +[22] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[6] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer InstituteMillennium Pharmaceuticals IncAmgen Inc
Inactive CompaniesDana-Farber Cancer InstituteThe University Of Texas MD Anderson Cancer CenterNantbioscience Inc +[4] 
Active IndicationsBone metastasesLung NeoplasmsNeuroectodermal Tumors, Primitive, Peripheral +[5] 
Inactive IndicationsSolid tumoursNeoplasm MetastasisProstatic Neoplasms +[17] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG